Hiển thị các bài đăng có nhãn halts. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn halts. Hiển thị tất cả bài đăng

Thứ Sáu, 26 tháng 4, 2013

Another HIV vaccine fails as government halts US study

  • vaccines istock.jpg

Bad news in the fight against the AIDS virus: The government is halting a large U.S. study of a possible HIV vaccine because the experimental shots aren't preventing infection.

The study had enrolled about 2,500 people, mostly gay men, in 19 cities. Half received an experimental vaccine developed by the National Institutes of Health, and half received dummy shots.

A safety review this week found that slightly more volunteers who had received the vaccine later became infected with HIV. It's not clear why.

The NIH said Thursday that it is stopping vaccinations, but will continue to study the volunteers' health.

Multiple attempts at creating an AIDS vaccine have failed over the years. But researchers continue to try, pointing to modest success in a 2009 study in Thailand.


View the original article here

Thứ Ba, 19 tháng 3, 2013

Mold in IV solution prompts recall, halts production of New Jersey pharmacy

  • IV-BAG.jpg

Another compounding pharmacy – this time in Tinton Falls, N.J. – has recalled a product after health care providers in a Connecticut hospital identified fungus in it, the U.S. Food and Drug Administration announced.

The health care providers found floating particles in five bags of magnesium sulfate IV solution made by Med Prep Consulting Inc., and the agency said the solution may have been distributed to other facilities in Connecticut, New Jersey, Pennsylvania and Delaware.

For the time being, the FDA is telling health care providers and facilities to stop using all products from Med Prep, saying they should be returned to the pharmacy.

“Giving a patient a contaminated injectable drug could result in a life-threatening infection,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research. “We do not have reports of patient infections. However, due to a lack of sterility assurance at the facility and out of abundance of caution, this recall is necessary to protect patients.”

The FDA is working with the U.S. Centers for Disease Control and Prevention, as well as state officials in New Jersey and Connecticut.

Med Prep has temporarily halted all production, including processing and shipping.

So far, there has not been any injury or illness related to the recalled product, but the FDA asks health care providers and/or consumers to report any adverse reactions to the MedWatch program.

Six months ago, nearly 17,000 contaminated steroids were manufactured and distributed through the U.S. by the New England Compounding Center in Massachusetts, and 50 people died from fungal meningitis and secondary infections.

Click for more from the FDA.


View the original article here

Thứ Tư, 27 tháng 2, 2013

FDA halts trials of Amgen drug in children after 14-year-old dies

The Food and Drug Administration said on Tuesday it has stopped all pediatric clinical trials of Amgen Inc's Sensipar after the death of a 14-year-old patient taking part in a study of the drug.

Sensipar, which is approved for adults, is used to lower dangerously high calcium levels in the blood.

The agency said it was collecting information on the circumstances of the teenager's death. It said it does not know if the Amgen drug had any role in the death.

"This communication is intended to inform health care professionals that we are evaluating the information and will communicate our final conclusions and recommendations when our review is complete," the FDA said in a statement posted on its website.

Amgen, the world's largest biotechnology company, said it had sent a letter last week to healthcare providers alerting them to the trials' halt and the patient death.

"Amgen is working as rapidly as possible to understand the circumstances of what happened. This analysis is ongoing and will be concluded as quickly as possible," the company said in a statement.

Sensipar works by decreasing the release of parathyroid hormone from the parathyroid gland to lower calcium levels in the blood. High levels of calcium in the blood can lead to serious health problems.

Sensipar, which had worldwide sales of $950 million in 2012, is approved to treat adults 18 and over. The trials were being conducted to determine the safety and efficacy of the drug in younger patients.

Drugmakers also often conduct pediatric trials because they are rewarded with an additional six months of patent protection for testing medicines in children.


View the original article here